12-羟基-十八烷酸2-羟基乙基酯 | 6284-41-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 12-羟基-十八烷酸2-羟基乙基酯
• 英文名称: solutol HS 15
• 英文别名: 12-hydroxy-octadecanoic acid-(2-hydroxy-ethyl ester)；12-Hydroxy-octadecansaeure-(2-hydroxy-aethylester)；12-Hydroxy-stearinsaeure-(2-hydroxy-aethylester)；Aethylenglykol-mono-(12-hydroxy-stearat)；polyethylene glycol 12-(hydroxy)stearate；polyethylene glycol 12-hydroxystearate；2-Hydroxyethyl 12-hydroxyoctadecanoate
• CAS: 6284-41-9
• 化学式: C₂₀H₄₀O₄
• 分子量: 344.535
• InChiKey: JVKUCNQGESRUCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  24
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  12-羟基硬脂酸 、 乙二醇 在 对甲苯磺酸 、 xylene 作用下， 生成 12-羟基-十八烷酸2-羟基乙基酯
  参考文献：
  名称：

  Bell; Taub, Journal of the American Pharmaceutical Association (1912), 1943, vol. 32, p. 116

  摘要：

  DOI：

文献信息

• AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20200377461A1

  公开（公告）日：2020-12-03

  An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

  一种氨基化合物，用作半羧酸敏感性氨基氧化酶（SSAO）和/或血管粘附蛋白-1（VAP-1）抑制剂，一种药物组合物，以及其在药物中的应用，可用于治疗炎症和/或与炎症相关的疾病，糖尿病和/或与糖尿病相关的疾病，精神障碍，缺血性疾病，血管疾病，纤维化或组织移植排斥。
• POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION
  申请人：PEKING UNIVERSITY FOUNDER GROUP CO., LTD.

  公开号：US20170029404A1

  公开（公告）日：2017-02-02

  The present invention provides a polysubstituted pyridine compound of Formula I, a preparation method, a use and a pharmaceutical composition thereof. The polysubstituted pyridine compound of Formula I according to the present invention has an excellent anti-tumor effect, can inhibit various cell kinases simultaneously, has significantly excellent pharmacokinetic characteristics, and is very suitable for oral and intravenous administration. The pharmaceutical composition according to the present invention can be useful for treating tumors and cancers.

  本发明提供了一种公式I的多取代吡啶化合物，以及其制备方法、用途和药物组合物。根据本发明，公式I的多取代吡啶化合物具有出色的抗肿瘤效果，可以同时抑制各种细胞激酶，具有显著优异的药代动力学特性，非常适合口服和静脉注射。根据本发明的药物组合物可用于治疗肿瘤和癌症。
• Polymerizable compositions and in-mold cured products using same
  申请人：Takemoto Yushi Kabushiki Kaisha

  公开号：EP0614918A1

  公开（公告）日：1994-09-14

  A polymerizable composition contains unsaturated urethane shown by Formula (1) given below, vinyl monomer which are copolymerizable with this unsaturated urethane, and an inorganic powder filler at weight ratio of (unsaturated urethane)/(vinyl monomer ) = 10/90-90/10, the inorganic powder filler being 30-300 weight parts with respect to 100 weight parts of the sum of the unsaturated urethane and vinyl monomer : where R¹ is hydrogen atom or methyl group; X is a residual group obtained by removing isocyanate groups from diisocyanate; Y is a residual group obtained by removing hydroxyl groups from non-radical polymerizable di-ol or tri-ol having alkyl group or alkenyl group with 5-22 carbon atoms; Z is an organic group in the form of (R²O)m or R³O, R² being an alkylene group with 2-4 carbon atoms, R³ being an alkylene group with 2-12 carbon atoms, and m being an integer 2-10; and n is 2 or 3.

  一种可聚合组合物含有下式（1）所示的不饱和聚氨酯、可与该不饱和聚氨酯共聚的乙烯基单体和无机粉末填料，重量比为（不饱和聚氨酯）/（乙烯基单体）=10/90-90/10，其中无机粉末填料占不饱和聚氨酯和乙烯基单体总重量 100 的 30-300 重量份： 其中 R¹ 是氢原子或甲基；X 是通过从二异氰酸酯中去除异氰酸酯基团而得到的残余基团；Y 是通过从具有 5-22 个碳原子的烷基或烯基的非辐射可聚合二元醇或三元醇中去除羟基而得到的残余基团；Z 是 (R²O)m 或 R³O 形式的有机基团，R² 是具有 2-4 个碳原子的亚烷基，R³ 是具有 2-12 个碳原子的亚烷基，m 是 2-10 的整数；n 是 2 或 3。
• PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF
  申请人：Tianjin Hemay Bio-Tech Co., Ltd.

  公开号：EP2394649A1

  公开（公告）日：2011-12-14

  The compositions formed from pyridyl cyanoguanidines and cyclodextrins, cyclodextrin derivatives and/or surfactants with solubilization, preparation methods and uses thereof.

  由吡啶基氰基胍和环糊精、环糊精衍生物和/或表面活性剂形成的组合物及其溶解、制备方法和用途。
• SPRAY-DRIED POWDER COMPRISING VANCOMYCIN HYDROCHLORIDE, AND INDUSTRIAL MANUFACTURING METHOD THEREOF
  申请人：Sun, Xinqiang

  公开号：EP2974716A1

  公开（公告）日：2016-01-20

  The present invention provides a spray-dried powder comprising vancomycin hydrochloride, and an industrial manufacturing method thereof. The industrial manufacturing method comprises: using a vancomycin hydrochloride solution with the purity of not lower than 95%, adding a stabilizing agent and a solubilizing agent in the solution to increase the stability and the concentration of the solution, concentrating the vancomycin hydrochloride composite solution to 20%-30wt.%, and performing spray drying in this concentration to obtain a vancomycin hydrochloride spray-dried powder with the impurity B of lower than 1.5%.

  本发明提供了一种含有盐酸万古霉素的喷雾干燥粉及其工业制造方法。该工业制造方法包括：使用纯度不低于95%的盐酸万古霉素溶液，在溶液中加入稳定剂和增溶剂，以提高溶液的稳定性和浓度，将盐酸万古霉素复合溶液浓缩至20%-30wt.%，在此浓度下进行喷雾干燥，得到杂质B低于1.5%的盐酸万古霉素喷雾干燥粉末。